Aurelie Cabannes-Hamy
Overview
Explore the profile of Aurelie Cabannes-Hamy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andrieu G, Simonin M, Cabannes-Hamy A, Lengline E, Marcais A, Theron A, et al.
Nat Commun
. 2025 Mar;
16(1):2191.
PMID: 40038309
The deregulated activation of the phosphoinositide 3-kinase (PI3K) pathway is a hallmark of aggressive tumors with metabolic plasticity, eliciting their adaptation to the microenvironment and resistance to chemotherapy. A significant...
2.
Courtois L, Pinton A, Cabannes-Hamy A, Simonin M, Andrieu G, Queri M, et al.
Blood
. 2025 Feb;
PMID: 39977715
Refractory and/or relapsing T-cell acute lymphoblastic leukemia (T-ALL) remains a major therapeutic challenge. The pre-TCR pathway has recently emerged as a therapeutic target via LCK inhibition in this context. However,...
3.
Lew-Derivry L, Chevillon F, Brice P, Bigenwald C, Landman-Parker J, Leblanc T, et al.
Br J Haematol
. 2025 Jan;
206(3):907-918.
PMID: 39756437
Hodgkin lymphoma (HL) is one of the most common cancers in adolescents and young adults (AYA). Paediatric and adult therapeutic strategies diverge while sharing the common objective: maintaining optimal efficacy...
4.
Rossi C, Manson G, Marouf A, Cabannes-Hamy A, Nicolas-Virelizier E, Maerevoet M, et al.
Eur J Cancer
. 2024 Nov;
213():115073.
PMID: 39509848
Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements...
5.
Walczak P, Fodil S, Vignal N, Cabannes-Hamy A, Boissel N, Raffoux E, et al.
Blood
. 2024 Jun;
144(10):1127-1130.
PMID: 38917352
Tyrosine kinase inhibitors efficacy in central nervous system (CNS) disease remains uncertain. Ponatinib was studied for CNS distribution in 16 patients with Philadelphia-positive acute lymphoblastic leukemia. Cerebrospinal fluid concentrations fell...
6.
Simonin M, Vasseur L, Lengline E, Lhermitte L, Cabannes-Hamy A, Balsat M, et al.
Blood
. 2024 Jun;
144(15):1570-1580.
PMID: 38848537
We previously reported a better outcome in adult and pediatric T-cell acute lymphoblastic leukemia (T-ALL) harboring NOTCH1 and/or FBXW7 mutations without alterations of K-N-RAS and PTEN genes. Availability of high-throughput...
7.
Guerineau H, Kohn M, Al Hamoud A, Sellier J, Osman J, Cabannes-Hamy A
Ann Hematol
. 2024 Apr;
103(6):2169-2171.
PMID: 38589717
We report the case of the youngest patient described with VEXAS syndrome associated with MDS-IB1, successfully treated with azacitidine-venetoclax and allogeneic stem cell transplant.
8.
Pinton A, Courtois L, Doublet C, Cabannes-Hamy A, Andrieu G, Smith C, et al.
Clin Cancer Res
. 2023 Oct;
30(1):94-105.
PMID: 37889114
Purpose: To assess the impact of PHF6 alterations on clinical outcome and therapeutical actionability in T-cell acute lymphoblastic leukemia (T-ALL). Experimental Design: We described PHF6 alterations in an adult cohort...
9.
Courtois L, Cabannes-Hamy A, Kim R, Delecourt M, Pinton A, Charbonnier G, et al.
Blood
. 2023 Apr;
142(2):158-171.
PMID: 37023368
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a dismal prognosis related to refractory/relapsing diseases, raising the need for new targeted therapies. Activating mutations of interleukin-7-receptor pathway...
10.
Vignal N, Kelly L, Lengline E, Cabannes-Hamy A, Siavellis J, Ghez D, et al.
Haematologica
. 2023 Feb;
108(9):2531-2534.
PMID: 36794507
No abstract available.